Liver cancer patients are welcoming good news today. The tumor marker heat shock protein 90α (Hsp90α) kit developed by the team of Luo Yongzhang of Tsinghua University has been approved for clinical use by the State Food and Drug Administration. The kit requires only a small amount of blood to detect early liver cancer and lung cancer, which can comprehensively improve the level of liver cancer prevention and control and reduce its mortality. In 2013, the National Engineering Laboratory of Anti-Tumor Protein Drugs of Tsinghua University passed the clinical trial of lung cancer, which proved that plasma Hsp90α is a brand new tumor marker. The State Food and Drug Administration approved the use of plasma Hsp90α as a marker for liver cancer, marking the birth of the first broad-spectrum tumor marker defined by Chinese scientists and approved for clinical use. At present, most patients with liver cancer have reached the middle and late stages of their discovery, and their survival expectation is generally poor. The alpha-fetoprotein (AFP), a clinically recognized marker for liver cancer detection, has a sensitivity of only about 50%. Hsp90α broke through the limitations of AFP. Herb Grinder,Wood Grinder,Weed Grinder,Tobacco Grinder Wenzhou Xinyu Imp & Exp Co.,Ltd , https://www.somgar.com
Tsinghua: The early detection of liver cancer kits approved for clinical use